These products are based upon Lamellar’s proprietary Lamellasome™ technology. Lamellasomes™ are mimetics of native extra-alveolar lamellar bodies.
These lipid vesicles regulate the key interfaces between internal tissues e.g. in the pleural cavity separating the chest wall and the lungs and between the body and the external environment as in the conducting airways of the lungs and in the mouth.
Research into the unique properties of extra-alveolar lamellar bodies has shown that many conditions are associated with dry or sticky mucosal surfaces e.g. Cystic Fibrosis, which could be modified by the application of Lamellasomes™.
Recognising the considerable clinical potential of lamellar bodies, the Company was established in June 2007 acquiring the intellectual property rights to Lamellasome™ technology with the aim of commercialising these unique and ubiquitous vesicles.
Collaborations are a key element of Lamellar’s strategy and the Company works closely with clinical centres-of-excellence to identify conditions where current treatment options are limited and/or expensive.
As a result Lamellar is working on the following therapeutic areas: